Joubert D, Mouhieddine B, Benlot C, Levy L, Peillon F
INSERM U223, Paris, France.
Horm Res. 1992;38(1-2):100-4. doi: 10.1159/000182501.
In contrast to normal human pituitaries, GH-secreting adenomas cannot process in vivo ProSRIH whereas they do it in vitro. The existence of an endogenous factor able to inhibit ProSRIH processing in vivo was postulated and such a role was analyzed for GHRH. Results showed that when GH adenomas are incubated in vitro with GHRH 10(-8) M, their ProSRIH contents are decreased, percent inhibition being negatively correlated to the amount of endogenously released GHRH. When incubation is performed in the presence of GHRH antibody in order to block the effect of endogenous GHRH, Pro-SRIH content is increased. The same effects are observed on SRIH release: inhibition by GHRH, stimulation by GHRH antibody. Normal rabbit serum had no effect. It may therefore be concluded that the absence of ProSRIH maturation observed in adenomas in vivo may be the consequence of the GHRH release that is known to be higher from GH adenomas than from normal pituitaries.
与正常人类垂体不同,分泌生长激素的腺瘤在体内无法处理前体促生长抑素(ProSRIH),而在体外却可以。推测存在一种能够在体内抑制ProSRIH加工的内源性因子,并对生长激素释放激素(GHRH)的这种作用进行了分析。结果表明,当生长激素腺瘤在体外与10^(-8) M的GHRH一起孵育时,其ProSRIH含量降低,抑制百分比与内源性释放的GHRH量呈负相关。当在GHRH抗体存在下进行孵育以阻断内源性GHRH的作用时,前体促生长抑素(Pro-SRIH)含量增加。对生长抑素(SRIH)释放也观察到相同的效果:GHRH抑制,GHRH抗体刺激。正常兔血清无作用。因此可以得出结论,在体内腺瘤中观察到的ProSRIH成熟缺失可能是GHRH释放的结果,已知生长激素腺瘤释放的GHRH高于正常垂体。